Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
J Med Genet ; 60(11): 1127-1132, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37055165

RESUMEN

Rothmund-Thomson syndrome (RTS) is a rare, heterogeneous autosomal recessive genodermatosis, with poikiloderma as its hallmark. It is classified into two types: type I, with biallelic variants in ANAPC1 and juvenile cataracts, and type II, with biallelic variants in RECQL4, increased cancer risk and no cataracts. We report on six Brazilian probands and two siblings of Swiss/Portuguese ancestry presenting with severe short stature, widespread poikiloderma and congenital ocular anomalies. Genomic and functional analysis revealed compound heterozygosis for a deep intronic splicing variant in trans with loss of function variants in DNA2, with reduction of the protein levels and impaired DNA double-strand break repair. The intronic variant is shared by all patients, as well as the Portuguese father of the European siblings, indicating a probable founder effect. Biallelic variants in DNA2 were previously associated with microcephalic osteodysplastic primordial dwarfism. Although the individuals reported here present a similar growth pattern, the presence of poikiloderma and ocular anomalies is unique. Thus, we have broadened the phenotypical spectrum of DNA2 mutations, incorporating clinical characteristics of RTS. Although a clear genotype-phenotype correlation cannot be definitively established at this moment, we speculate that the residual activity of the splicing variant allele could be responsible for the distinct manifestations of DNA2-related syndromes.

2.
Horm Res Paediatr ; 94(11-12): 410-415, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34610594

RESUMEN

BACKGROUND/AIMS: Obesity leads to increased risk of thromboembolic events in adults, but few studies have addressed the relationship between obesity and thrombogenic risk during childhood. The aim of this study was to evaluate the prothrombotic state of obese children in comparison with healthy children. METHODS: Thrombin generation, fibrinogen, and D-dimer levels, along with metabolic parameters, were measured in 72 prepubertal children, of which 47 were obese and 25 eutrophic. RESULTS: A significant increase in thrombin generation, fibrinogen, and dyslipidemia was found among obese patients. CONCLUSION: A prothrombotic state develops in childhood obesity during the prepubertal phase.


Asunto(s)
Enfermedades Cardiovasculares , Obesidad Infantil , Adulto , Índice de Masa Corporal , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/etiología , Niño , Fibrinógeno/análisis , Fibrinógeno/metabolismo , Factores de Riesgo de Enfermedad Cardiaca , Humanos , Obesidad Infantil/complicaciones , Factores de Riesgo
3.
Pediatr Endocrinol Rev ; 17(3): 243-249, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32741155

RESUMEN

BACKGROUND: Ovotesticular Difference of Sex Development (OT DSD) is a rare condition characterized by histologic demonstration of ovarian and testicular tissue in the same individual. Descriptions in literature usually do not include long term follow-up data. OBJECTIVES: The aim of this study is to describe clinical, biochemical and histological findings, as well as long term outcomes (including onset and progression of puberty) in patients with OT DSD. RESULTS: In a retrospective study of 31 patients, findings include predominantly male gender assignment at the time of referral (54.8%) and subsequent female gender of rearing (54.8%). The most frequent karyotype was 46,XX (58.1%). Ovotestis was the most frequent gonad (48.4%) Puberty could be evaluated in 20 patients, being spontaneous in 12 of them. Four patients with partial gonadectomy in infancy were able to enter female puberty spontaneously. CONCLUSION: It was observed that patients who preserved gonadal tissues were able to enter puberty spontaneously.


Asunto(s)
Trastornos del Desarrollo Sexual , Trastornos Ovotesticulares del Desarrollo Sexual , Femenino , Humanos , Masculino , Pubertad , Estudios Retrospectivos
4.
Sex Dev ; 14(1-6): 3-11, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33652437

RESUMEN

In this study, we present 3 cases of Down syndrome (DS) associated with disorders/differences of sex development (DSD) and review the literature on this topic. Case 1: 1-year-old child with male genitalia and DS phenotype, 47,XX,+21 karyotype and testicular DSD. Case 2: 11-month-old child with male genitalia and few DS dysmorphisms, 45,X/47,XY,+21 karyotype, and mixed gonadal dysgenesis. Case 3: 4-month-old child with female genitalia and DS phenotype, 47,XY,+21 karyotype and XY complete gonadal dysgenesis. In the literature, among 188 patients, 107 (57%) had Klinefelter syndrome and 61 (33%) Turner syndrome, 12 (6%) had mixed gonadal dysgenesis, 2 (1%) had partial androgen insensitivity, 2 (1%) ovotesticular DSD, and the others had congenital adrenal hyperplasia, XY partial gonadal dysgenesis, XY complete gonadal dysgenesis, and complete androgen insensitivity (1 case each). A typical DS phenotype was found in all individuals of the revision, with the exception of one case, but DSD features were not always reported. In conclusion, the association of DS with sex chromosome DSD is the most frequently observed, whereas associations with 46,XX and 46,XY DSD is extremely rare.

5.
Arch. endocrinol. metab. (Online) ; 61(6): 608-613, Dec. 2017. tab, graf
Artículo en Inglés | LILACS | ID: biblio-887613

RESUMEN

ABSTRACT Objective: The objective was to conduct clinical and metabolic evaluations of obese adolescents before and after laparoscopic sleeve gastrectomy (LSG) (up to 24 months). Subjects and methods: This was designed as a retrospective, descriptive series of cases study, conducted in Instituto da Criança, São Paulo, Brazil. Analysis of clinical and laboratory data from 22 obese adolescents between 14 and 19 years old submitted to LSG between 2007 and 2014. Patients had BMI > 40 kg/m2 or BMI > 35 kg/m2 with comorbidities. Anthropometric, clinical and laboratory assessments were performed: before surgery, 6, 12, 18, and 24 months after surgery. We assessed weight loss and metabolic changes up to 24 months after LSG. Results: The mean preoperative weight and BMI were 128.5 kg (SD = 23.1) and 46.5 kg/m2 (SD = 74), respectively. There was an average weight loss of 34.5 kg in the first 12 months' post LSG, corresponding to a 60% excess weight loss (EWL), as well as an average reduction in BMI of 12.3 kg/m2. However, after 24 months, the average EWL was 45%, corresponding to an average weight regain (WR) of 13.3 kg (15%) within two years. LSG improved dyslipidemia in 67.8% of patients, a significant remission of hepatic steatosis 47% and 37.7% systemic arterial hypertension; type 2 diabetes remission was complete. Conclusions: LSG proved to be a safe and effective procedure and seems to be the new hope for the obesity epidemic.


Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto Joven , Obesidad Mórbida/cirugía , Laparoscopía/métodos , Obesidad Infantil/cirugía , Gastrectomía/métodos , Obesidad Mórbida/sangre , Estudios Retrospectivos , Resultado del Tratamiento
6.
Arch Endocrinol Metab ; 61(6): 608-613, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29412386

RESUMEN

OBJECTIVE: The objective was to conduct clinical and metabolic evaluations of obese adolescents before and after laparoscopic sleeve gastrectomy (LSG) (up to 24 months). SUBJECTS AND METHODS: This was designed as a retrospective, descriptive series of cases study, conducted in Instituto da Criança, São Paulo, Brazil. Analysis of clinical and laboratory data from 22 obese adolescents between 14 and 19 years old submitted to LSG between 2007 and 2014. Patients had BMI > 40 kg/m2 or BMI > 35 kg/m2 with comorbidities. Anthropometric, clinical and laboratory assessments were performed: before surgery, 6, 12, 18, and 24 months after surgery. We assessed weight loss and metabolic changes up to 24 months after LSG. RESULTS: The mean preoperative weight and BMI were 128.5 kg (SD = 23.1) and 46.5 kg/m2 (SD = 74), respectively. There was an average weight loss of 34.5 kg in the first 12 months' post LSG, corresponding to a 60% excess weight loss (EWL), as well as an average reduction in BMI of 12.3 kg/m2. However, after 24 months, the average EWL was 45%, corresponding to an average weight regain (WR) of 13.3 kg (15%) within two years. LSG improved dyslipidemia in 67.8% of patients, a significant remission of hepatic steatosis 47% and 37.7% systemic arterial hypertension; type 2 diabetes remission was complete. CONCLUSIONS: LSG proved to be a safe and effective procedure and seems to be the new hope for the obesity epidemic.


Asunto(s)
Gastrectomía/métodos , Laparoscopía/métodos , Obesidad Mórbida/cirugía , Obesidad Infantil/cirugía , Adolescente , Femenino , Humanos , Masculino , Obesidad Mórbida/sangre , Estudios Retrospectivos , Resultado del Tratamiento , Adulto Joven
7.
Rev Assoc Med Bras (1992) ; 62(6): 594-601, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27849238

RESUMEN

The International Diabetes Federation (IDF-2015) estimates the existence of 30,900 children under 15 years old with type 1 diabetes mellitus (DM1) in Brazil, and an increase of 3.0% per year is expected. This review focused on meta-analysis and pediatric diabetes update articles in order to draw attention to the need of planning coping strategies to support this serious public health problem in coming years. DM1 is considered an immuno-mediated disease with a complex transmission influenced by genetic and environmental factors responsible for a gradual destruction of the insulin producing pancreatic beta cells. Seroconversion to DM1-associated autoantibodies and abnormalities in metabolic tests that assess insulin secretion and glucose tolerance can be used as predictive criteria of beta cells functional reserve and the onset of the clinical disease. Symptomatic DM1 treatment is complex and the maintenance of good metabolic control is still the only effective strategy for preserving beta cell function. Disease duration and hyperglycemia are both risk factors for the onset of chronic vascular complications that negatively affect the quality of life and survival of these patients. In this regard, health teams must be trained to provide the best possible information on pediatric diabetes, through continuing education programs focused on enabling these young people and their families to diabetes self-management.


Asunto(s)
Diabetes Mellitus Tipo 1/epidemiología , Brasil/epidemiología , Preescolar , Diabetes Mellitus Tipo 1/fisiopatología , Humanos , Factores de Riesgo
8.
Rev. Assoc. Med. Bras. (1992, Impr.) ; Rev. Assoc. Med. Bras. (1992, Impr.);62(6): 594-601, Sept. 2016. tab, graf
Artículo en Inglés | LILACS | ID: biblio-829498

RESUMEN

Summary The International Diabetes Federation (IDF-2015) estimates the existence of 30,900 children under 15 years old with type 1 diabetes mellitus (DM1) in Brazil, and an increase of 3.0% per year is expected. This review focused on meta-analysis and pediatric diabetes update articles in order to draw attention to the need of planning coping strategies to support this serious public health problem in coming years. DM1 is considered an immuno-mediated disease with a complex transmission influenced by genetic and environmental factors responsible for a gradual destruction of the insulin producing pancreatic beta cells. Seroconversion to DM1-associated autoantibodies and abnormalities in metabolic tests that assess insulin secretion and glucose tolerance can be used as predictive criteria of beta cells functional reserve and the onset of the clinical disease. Symptomatic DM1 treatment is complex and the maintenance of good metabolic control is still the only effective strategy for preserving beta cell function. Disease duration and hyperglycemia are both risk factors for the onset of chronic vascular complications that negatively affect the quality of life and survival of these patients. In this regard, health teams must be trained to provide the best possible information on pediatric diabetes, through continuing education programs focused on enabling these young people and their families to diabetes self-management.


Resumo A Federação Internacional de Diabetes (IDF-2015) estima a existência no Brasil de 30.900 menores de 15 anos portadores de diabetes mellitus tipo 1 (DM1), com previsão de aumento de 3,0% ao ano. Esta revisão buscou artigos de metanálise e atualização em diabetes infantil com o objetivo de alertar para a necessidade do planejamento de estratégias de enfrentamento deste que tende a ser um sério problema de saúde pública para os próximos anos. O DM1 é considerado uma doença imunomediada de transmissão complexa, influenciada por fatores genéticos e ambientais determinantes da destruição gradual das células beta pancreáticas produtoras de insulina. A positividade sorológica dos autoanticorpos associados ao DM1 e a alteração de testes metabólicos que avaliam a secreção de insulina e o estado glicêmico podem ser utilizados como critérios de previsão da reserva funcional de células beta e do início clínico da doença. O tratamento do DM1 sintomático é complexo, e a manutenção do bom controle metabólico é ainda a única estratégia efetiva de preservação das células beta ainda funcionantes. Tempo de duração da doença e hiperglicemia são fatores de risco para a instalação das complicações vasculares crônicas, que afetam negativamente a qualidade de vida e a sobrevida desses indivíduos. Torna-se necessária a formação de equipes de saúde preparadas para fornecer a melhor informação possível em diabetes infantil, através de programas de educação continuada, com potencial de capacitar esses jovens e suas famílias para o autocuidado.


Asunto(s)
Humanos , Preescolar , Diabetes Mellitus Tipo 1/fisiopatología , Brasil/epidemiología , Factores de Riesgo , Diabetes Mellitus Tipo 1/epidemiología
9.
Horm Res Paediatr ; 82(5): 319-23, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25322903

RESUMEN

BACKGROUND: Follow-up visits of patients recovering from anorexia nervosa (AN) have shown that some patients do not resume menstrual cycles despite returning to the normal weight for their age and height. AIM: To verify whether leptin, insulin-like growth factor 1 (IGF-1) or another hormonal marker could be a good predictor of the return of menses. PATIENTS AND METHODS: This prospective study included female adolescents diagnosed with AN or eating disorders not otherwise specified (EDNOS) and who were being treated in an ambulatory care unit during nutritional recovery. Body mass index and leptin, luteinizing hormone, estradiol and IGF-1 levels of these patients were evaluated. Blood samples were collected in the 1st (T1), 5th (T2), 10th (T3), 15th (T4) and 20th (T5) weeks of treatment. The hormone levels during nutritional recovery and at the time of the resumption of menses were analyzed. RESULTS: The hormonal profiles improved after nutritional recovery, with IGF-1 correlating the most with the resumption of menses and nutritional recovery (p = 0.0001). At the resumption of menstruation, the patients showed IGF-1 levels >342.8 ng/ml. CONCLUSION: IGF-1 was the best predictor of the return of menses in female adolescents with AN or EDNOS.


Asunto(s)
Anorexia Nerviosa/sangre , Índice de Masa Corporal , Factor I del Crecimiento Similar a la Insulina/metabolismo , Ciclo Menstrual , Adolescente , Anorexia Nerviosa/dietoterapia , Anorexia Nerviosa/fisiopatología , Niño , Femenino , Estudios de Seguimiento , Humanos , Leptina/sangre , Hormona Luteinizante/sangre , Estudios Prospectivos
10.
Pediatr. mod ; 50(1)jan. 2014.
Artículo en Portugués | LILACS | ID: lil-712196

RESUMEN

Os autores repassam os mecanismos fisiológicos envolvidos no crescimento intrauterino e pós-natal, bem como as principais causas de baixa estatura. A importância da anamnese e do exame físico é enfatizada, juntamente com uma avaliação laboratorial e de imagem que permita situar a criança num contexto diagnóstico e propor um tratamento. Enfatiza-se a dificuldade de estabelecer o diagnóstico etiológico em grande número de casos e a importância da saúde geral no crescimento normal, implicando em que as doenças crônicas se constituem em causa importante de baixa estatura. Em termos de tratamento, nem sempre é a administração de hormônio de crescimento necessária para que se normalize o crescimento. No entanto, atualmente muitas indicações de hormônio de crescimento recombinante humano prescindem da demonstração de deficiência na produção hormonal e muitas situações clínicas, como a síndrome de Turner, o pequeno para a idade gestacional e a baixa estatura idiopática se beneficiam do tratamento, mesmo que não sejam deficientes em hormônio de crescimento. A demora do encaminhamento de uma criança com baixa estatura pelo pediatra pode significar uma perda irreparável em sua altura final e fica a mensagem de que nosso objetivo básico é propiciar que a criança desfrute de seu pleno potencial genético e não ter por objetivo "criar um gigante" ou uma criança acima de suas possibilidades de crescimento. Dar falsas expectativas sobre o crescimento de uma criança pode ser mais deletério do que informar a real capacidade de crescimento que esta criança em particular possui e valorizá-la da forma que é, pois crescimento não é sinônimo de "sucesso na vida"...


Asunto(s)
Humanos , Masculino , Femenino , Niño , Crecimiento , Niño , Terapéutica
11.
Arq. bras. endocrinol. metab ; Arq. bras. endocrinol. metab;56(8): 496-500, Nov. 2012. ilus, tab
Artículo en Inglés | LILACS | ID: lil-660256

RESUMEN

We report a case of adrenal hypoplasia congenita (AHC) and hypogonadotropic hypogonadism (HH) due to a novel DAX1 mutation. A 19-month-old boy with hyperpigmentation and failure to thrive came to our service for investigation. Three brothers of the patient had died due to adrenal failure, and a maternal cousin had adrenal insufficiency. Adrenoleukodystrophy was excluded. MRI showed normal pituitary and hypothalamus. Plasma hormone evaluation revealed high ACTH (up to 2,790 pg/mL), and low levels of androstenedione, DHEA-S, 11-deoxycortisol, and cortisol. At 14 years of age the patient was still prepubescent, his weight was 43.6 kg (SDS: -0.87) and his height was 161 cm (SDS: -0.36), with normal body proportions. In the GnRH test, basal and maximum values of LH and FSH were respectively 0.6/2.1 and < 1.0/< 1.0 U/L. Molecular investigation identified a novel mutation that consists of a deletion of codon 372 (AAC; asparagine) in exon 1 of DAX1. This mutation was not found in a study of 200 alleles from normal individuals. Prediction site analysis indicated that this alteration, located in the DAX1 ligand-binding domain, may damage DAX1 protein. We hypothesize that the novel (p.Asp372del) DAX1 mutation might be able to cause a disruption of DAX1 function, and is probably involved in the development of AHC and HH in this patient. Arq Bras Endocrinol Metab. 2012;56(8):496-500.


Relatamos um caso de hipoplasia adrenal congênita (HAC) e hipogonadismo hipogonadotrófico (HH) causado por uma nova mutação do gene DAX1. Paciente do sexo masculino com 19 meses de idade, hiperpigmentação e desenvolvimento inadequado foi encaminhado ao nosso serviço. Antecedente familiar de três irmãos falecidos por falência da adrenal, e um primo materno portador de insuficiência adrenal. Excluída a hipótese de adrenoleucodistrofia. A RM demonstrou hipófise e hipotálamo normais. Os níveis de hormônios plasmáticos mostraram alta concentração de ACTH (até 2.790 pg/mL) e baixos níveis de androstenediona, DHEA-S, 11-deoxicortisol e cortisol. Aos 14 anos de idade, o paciente ainda era pré-púbere, com peso de 43,6 kg (SDS: -0,87) e altura de 161 cm (SDS: -0,36), proporcionado. O teste do GnRH mostrou níveis basais e máximos de LH e FSH, respectivamente, iguais a 0,6/2,1 e < 1,0/< 1,0 U/L. A análise molecular identificou uma nova mutação que consiste da deleção do códon 372 (AAC; asparagina) no éxon 1 do gene DAX1. Essa mutação não foi encontrada em 200 alelos de indivíduos normais. A análise no site PredictProtein indicou que essa alteração, localizada no domínio de ligação do DAX1, pode danificar a proteína. Nossa hipótese é que essa nova mutação (p.Asp372del) do gene DAX1 pode levar a uma alteração na função da proteína DAX1 e está provavelmente envolvida no desenvolvimento da HAC e HH nesse paciente. Arq Bras Endocrinol Metab. 2012;56(8):496-500.


Asunto(s)
Humanos , Lactante , Masculino , Hiperplasia Suprarrenal Congénita/genética , Receptor Nuclear Huérfano DAX-1/genética , Enfermedades Genéticas Ligadas al Cromosoma X/genética , Hipogonadismo/genética , Mutación/genética , Linaje
12.
Arq Bras Endocrinol Metabol ; 56(8): 496-500, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23295288

RESUMEN

We report a case of adrenal hypoplasia congenita (AHC) and hypogonadotropic hypogonadism (HH) due to a novel DAX1 mutation. A 19-month-old boy with hyperpigmentation and failure to thrive came to our service for investigation. Three brothers of the patient had died due to adrenal failure, and a maternal cousin had adrenal insufficiency. Adrenoleukodystrophy was excluded. MRI showed normal pituitary and hypothalamus. Plasma hormone evaluation revealed high ACTH (up to 2,790 pg/mL), and low levels of androstenedione, DHEA-S, 11-deoxycortisol, and cortisol. At 14 years of age the patient was still prepubescent, his weight was 43.6 kg (SDS: -0.87) and his height was 161 cm (SDS: -0.36), with normal body proportions. In the GnRH test, basal and maximum values of LH and FSH were respectively 0.6/2.1 and < 1.0/< 1.0 U/L. Molecular investigation identified a novel mutation that consists of a deletion of codon 372 (AAC; asparagine) in exon 1 of DAX1. This mutation was not found in a study of 200 alleles from normal individuals. Prediction site analysis indicated that this alteration, located in the DAX1 ligand-binding domain, may damage DAX1 protein. We hypothesize that the novel (p.Asp372del) DAX1 mutation might be able to cause a disruption of DAX1 function, and is probably involved in the development of AHC and HH in this patient.


Asunto(s)
Hiperplasia Suprarrenal Congénita/genética , Receptor Nuclear Huérfano DAX-1/genética , Enfermedades Genéticas Ligadas al Cromosoma X/genética , Hipogonadismo/genética , Mutación/genética , Insuficiencia Suprarrenal , Humanos , Insuficiencia Corticosuprarrenal Familiar , Lactante , Masculino , Linaje
13.
Arq Bras Endocrinol Metabol ; 53(6): 716-20, 2009 Aug.
Artículo en Portugués | MEDLINE | ID: mdl-19893913

RESUMEN

OBJECTIVES: To describe the presence of prostatic tissue in 46,XX patients with the classical form of congenital adrenal hyperplasia (CAH); to evaluate the sensitivity and specificity of prostatic specific antigen (PSA) measured in congenital adrenal hyperplasia patients with regard to the detection of prostatic tissue in pelvic MRI. METHODS: We studied 52 children and adolescents, 32 with the classical form of congenital adrenal hyperplasia, 10 boys and 10 girls without CAH. Pelvic MRI was performed in all patients to detect prostatic tissue. Prostate specific antigen, testosterone and dihydrotestosterone were measured in all patients. We used Receiver Operating Characteristic Curve for PSA discrimination capacity. RESULTS: Five girls with congenital adrenal hyperplasia showed image of prostatic tissue on pelvic MRI. Prostate specific antigen showed sensitivity and specificity of 100% and 88.9%, respectively, taking 0.1 ng/mL as the cutoff level. CONCLUSIONS: The incidence of prostatic tissue in 46,XX patients with the classical form of congenital adrenal hyperplasia was 15.6%. PSA demonstrated to be a good marker of prostatic tissue in these patients and should be used to screen patients to be submitted to image studies.


Asunto(s)
Hiperplasia Suprarrenal Congénita/patología , Dihidrotestosterona/sangre , Antígeno Prostático Específico/sangre , Próstata/patología , Testosterona/sangre , Adolescente , Hiperplasia Suprarrenal Congénita/sangre , Hiperplasia Suprarrenal Congénita/genética , Biomarcadores de Tumor/sangre , Estudios de Casos y Controles , Niño , Femenino , Humanos , Cariotipificación , Imagen por Resonancia Magnética , Masculino , Curva ROC , Sensibilidad y Especificidad , Procesos de Determinación del Sexo , Adulto Joven
14.
Arq. bras. endocrinol. metab ; Arq. bras. endocrinol. metab;53(6): 716-720, ago. 2009. ilus, graf, tab
Artículo en Portugués | LILACS | ID: lil-529948

RESUMEN

OBJETIVOS: Verificar a ocorrência de tecido prostático em pacientes portadoras da forma clássica de hiperplasia congênita das suprarrenais, com cariótipo 46,XX e analisar a sensibilidade e a especificidade do antígeno prostático específico (PSA) das pacientes com hiperplasia congênita das suprarrenais em relação à detecção de tecido prostático na ressonância magnética (RNM) de região pélvica. MÉTODOS: Foram estudadas 52 crianças e adolescentes, sendo 32 meninas portadoras da forma clássica de hiperplasia congênita das suprarrenais, 10 meninas e 10 meninos sem hiperplasia congênita das suprarrenais. A RNM da região pélvica e a coleta de PSA, diidrotestosterona e testosterona foram realizadas em todos os pacientes. Para analisar a capacidade de discriminação do antígeno prostático-específico, foi utilizada a curva ROC (receiver operating characteristic curve). RESULTADOS: Cinco das 32 pacientes portadoras de hiperplasia congênita das suprarrenais apresentaram tecido prostático na RNM de região pélvica. Para concentração de antígeno prostático-específico de 0,1 ng/mL, obteve-se sensibilidade de 100 por cento e especificidade de 88,9 por cento para a detecção de tecido prostático. CONCLUSÕES: A ocorrência de tecido prostático nas pacientes portadoras de hiperplasia congênita das suprarrenais estudadas foi de 15,6 por cento. O antígeno prostático-específico mostrou ser valioso marcador de tecido prostático nestas pacientes.


OBJECTIVES: To describe the presence of prostatic tissue in 46,XX patients with the classical form of congenital adrenal hyperplasia (CAH); to evaluate the sensitivity and specificity of prostatic specific antigen (PSA) measured in congenital adrenal hyperplasia patients with regard to the detection of prostatic tissue in pelvic MRI. METHODS: We studied 52 children and adolescents, 32 with the classical form of congenital adrenal hyperplasia, 10 boys and 10 girls without CAH. Pelvic MRI was performed in all patients to detect prostatic tissue. Prostate specific antigen, testosterone and dihydrotestosterone were measured in all patients. We used Receiver Operating Characteristic Curve for PSA discrimination capacity. RESULTS: Five girls with congenital adrenal hyperplasia showed image of prostatic tissue on pelvic MRI. Prostate specific antigen showed sensitivity and specificity of 100 percent and 88.9 percent, respectively, taking 0.1 ng/mL as the cutoff level. CONCLUSIONS: The incidence of prostatic tissue in 46,XX patients with the classical form of congenital adrenal hyperplasia was 15.6 percent. PSA demonstrated to be a good marker of prostatic tissue in these patients and should be used to screen patients to be submitted to image studies.


Asunto(s)
Adolescente , Niño , Femenino , Humanos , Masculino , Adulto Joven , Hiperplasia Suprarrenal Congénita/patología , Dihidrotestosterona/sangre , Antígeno Prostático Específico/sangre , Próstata/patología , Testosterona/sangre , Hiperplasia Suprarrenal Congénita/sangre , Hiperplasia Suprarrenal Congénita/genética , Estudios de Casos y Controles , Cariotipificación , Imagen por Resonancia Magnética , Curva ROC , Sensibilidad y Especificidad , Procesos de Determinación del Sexo , Biomarcadores de Tumor/sangre , Adulto Joven
15.
Diabetes Care ; 28(8): 1856-61, 2005 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16043723

RESUMEN

OBJECTIVE: To look for technical simplification and economic efficiency in the treatment of pediatric diabetic ketoacidosis (DKA) with subcutaneous use of the fast-acting insulin analog (lispro) and compare its use with regular intravenous insulin treatment. RESEARCH DESIGN AND METHODS: In this controlled clinical trial from June 2001 to June 2003, we randomized 60 episodes of DKA with a blood glucose level > or = 16.6 mmol/l (300 mg/dl), venous pH <7.3 and/or bicarbonate <15 mmol/l, or ketonuria greater than + +. Of the 60 episodes, 30 were treated with subcutaneous lispro (0.15 units/kg) given every 2 h (lispro group) and the other 30 cases received continuous intravenous regular insulin (0.1 unit x kg(-1) x h(-1); CIRI group). Volume deficit was repaired with 10-ml/kg aliquots of 0.9% sodium chloride. Laboratory monitoring included hourly bedside capillary glucose, venous blood gas, beta-hydroxybutyrate, and electrolytes. Plasma blood glucose levels were measured on admission, 2 h after admission, when capillary blood glucose reached < or = 13.8 mmol/l (250 mg/dl), and 6, 12, and 24 h thereafter. RESULTS: Capillary glucose levels decreased by 2.9 and 2.6 mmol x l(-1) x h(-1) in the lispro and CIRI groups, respectively, but blood glucose fluctuated at different time intervals. In the CIRI group, metabolic acidosis and ketosis resolved in the first 6-h period after capillary glucose reached 13.8 mmol/l, whereas in the lispro group, they resolved in the next 6-h interval; however, both groups met DKA recovery criteria without complications. CONCLUSIONS: DKA treatment with a subcutaneous fast-acting insulin analog represents a cost-effective and technically simplified procedure that precludes intensive care unit admission.


Asunto(s)
Diabetes Mellitus Tipo 1/tratamiento farmacológico , Insulina/análogos & derivados , Insulina/uso terapéutico , Glucemia/metabolismo , Niño , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/psicología , Cetoacidosis Diabética/prevención & control , Femenino , Humanos , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/uso terapéutico , Inyecciones Subcutáneas , Insulina/administración & dosificación , Insulina/efectos adversos , Insulina Lispro , Masculino , Cooperación del Paciente
16.
Arq. bras. endocrinol. metab ; Arq. bras. endocrinol. metab;49(1): 103-111, jan.-fev. 2005. ilus, tab
Artículo en Portugués | LILACS | ID: lil-399052

RESUMEN

OBJETIVO: Apresentar a experiência relativa a pacientes com deficiência da enzima 5alfa-redutase tipo 2 provenientes de três serviços distintos no Brasil. CASUíSTICA E MÉTODOS: Foram incluídos 25 pacientes com sinais clínicos e hormonais de deficiência da 5alfa-redutase 2 pertencentes a 23 famílias, 15 oriundas da Bahia, 7 de São Paulo e 1 de Minas Gerais. Foram avaliados dados clínicos, hormonais e moleculares. A análise molecular dos 5 éxons do gene SRD5A2 foi feita por meio da técnica de PCR, seguida de seqüenciamento automático ou manual. RESULTADOS: Em 10 famílias havia mutações no gene SRD5A2 em homozigose (5 com G183S, 2 com R246W, 1 com G196S, 1 com del642T, 1 com 217_218insC) e em 3 em heterozigose composta (1 com Q126R/IVS3+1G>A, 1 com Q126R/del418T e 1 com Q126R/G158R); em 3 casos os afetados eram heterozigotos, apresentando apenas uma mutação deletéria (1 com G196S, 1 com A207D e 1 com R246W). Em 7 casos não foram detectadas anormalidades ao seqüenciamento. Observou-se maior freqüência da G183S em pacientes miscigenados (Afro-Euro-Brasileiros) oriundos da Bahia. Os achados clínicos e hormonais não diferiram entre os casos com e sem mutação, à exceção da freqüência de consangüinidade e da maior gravidade da ambigüidade genital nos primeiros. CONCLUSÕES: Os resultados encontrados salientam a importância da investigação molecular para o diagnóstico dessa doença, ressaltando o achado de uma mutação bastante freqüente em nosso meio (G183S), especialmente em pacientes miscigenados oriundos da Bahia, e a descrição de mutações que até o momento só foram relatadas em pacientes brasileiros.


Asunto(s)
Adolescente , Adulto , Niño , Preescolar , Humanos , Lactante , Recién Nacido , Masculino , Trastornos del Desarrollo Sexual , /deficiencia , Brasil , Trastornos del Desarrollo Sexual , Mutación , /genética
17.
Arq Bras Endocrinol Metabol ; 49(1): 103-11, 2005 Feb.
Artículo en Portugués | MEDLINE | ID: mdl-16544041

RESUMEN

OBJECTIVE: To report the experience regarding patients with steroid 5alpha-reductase type 2 deficiency from three different clinical services in Brazil. CASUISTIC AND METHODS: Twenty five patients with clinical and hormonal features of 5alpha-reductase deficiency from 23 families (15 from Bahia, 7 from São Paulo and 1 from Minas Gerais) were included in this study. Clinical, hormonal and molecular data were evaluated. The molecular analysis of the five exons of the SRD5A2 gene was done by automatic or manual sequencing of PCR products. RESULTS: In ten families, SRD5A2 mutations were found in homozygosis (5 with G183S, 2 with R246W, 1 with G196S, 1 with del642T, 1 with 217_218insC), in three in compound heterozygosis (1 with Q126R/IVS3+1G>A, 1 with Q126R/del418T, 1 with Q126R/G158R) while other three were heterozygous, with only one deleterious mutation (1 with G196S, 1 with A207D, and 1 with R246W). In seven cases, no sequencing abnormalities were detected. The G183S substitution was the most frequently found among miscegenated patients (Afro-Euro-Brazilians) from Bahia. Hormonal and clinical findings did not differ between patients with or without mutations, exception made to a higher frequency of consanguinity and greater severity of genital ambiguity in the first group. CONCLUSION: Our results reinforce the importance of molecular investigation for the diagnosis of this disease and point out to the finding of a very frequent mutation (G183S) in our series, especially in patients with mixed ethnic background from Bahia, and the description of mutations that have only been reported in Brazilian patients so far.


Asunto(s)
3-Oxo-5-alfa-Esteroide 4-Deshidrogenasa/deficiencia , Trastornos del Desarrollo Sexual/enzimología , 3-Oxo-5-alfa-Esteroide 4-Deshidrogenasa/genética , Adolescente , Adulto , Brasil , Niño , Preescolar , Trastornos del Desarrollo Sexual/genética , Humanos , Lactante , Recién Nacido , Masculino , Mutación
18.
J Pediatr Endocrinol Metab ; 18(12): 1383-9, 2005 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-16459464

RESUMEN

AIM: To evaluate anti-Müllerian hormone (AMH) levels in patients with clinical and molecular diagnosis of 5alpha-reductase 2 deficiency. PATIENTS AND METHODS: Data from 14 patients whose age ranged from 21 days to 29 years were analyzed according to age and pubertal stage. Sexual ambiguity was rated as Prader III in 11 patients. LH, FSH, testosterone (T), dihydrotestosterone (DHT) and AMH serum levels were measured in all but two patients, who had been previously submitted to gonadectomy; T and DHT were also measured in 20 age-matched controls. RESULTS: Gonadotropin levels were normal in all but one patient who retained gonads (six of whom had reached puberty) and T/DHT ratio was elevated in all patients when compared to controls. All prepubertal patients had AMH levels < -1 SD for age, while most pubertal patients had AMH levels compatible with pubertal stage. CONCLUSIONS: Prepubertal patients with 5alpha-reductase 2 deficiency have AMH values in the lower part of the normal range. These data indicate that T does not need to be converted to DHT to inhibit AMH secretion by Sertoli cells.


Asunto(s)
3-Oxo-5-alfa-Esteroide 4-Deshidrogenasa/deficiencia , Glicoproteínas/fisiología , Hormonas Testiculares/fisiología , 3-Oxo-5-alfa-Esteroide 4-Deshidrogenasa/genética , Adolescente , Adulto , Hormona Antimülleriana , Estudios de Casos y Controles , Niño , Preescolar , Dihidrotestosterona/sangre , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Orquiectomía , Testosterona/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...